Urology | Home | MIMS Malaysia

Body image problems common among prostate cancer patients undergoing ADT

an hour ago

Dissatisfaction with body image is common among men receiving androgen deprivation therapy (ADT), a new study has shown. Exercise is seen as a means to counterbalance the side effect of treatment and improve mood.

TITAN seals a win for apalutamide + ADT in mCSPC

Pearl Toh, 16 hours ago

Adding apalutamide to androgen-deprivation therapy (ADT) significantly extends radiographic progression-free survival (rPFS) and overall survival (OS) in patients with metastatic castration-sensitive prostate cancer (mCSPC) compared with ADT alone, the TITAN* study shows.

Enzalutamide shows potential survival benefit in metastatic hormone-sensitive prostate cancer

Roshini Claire Anthony, 2 days ago

Men with metastatic hormone-sensitive prostate cancer (mHSPC) who receive testosterone suppression therapy may have a better survival outcome with the addition of enzalutamide over other non-steroidal anti-androgen (NSAA) therapies, according to the phase III ENZAMET* trial.

Constipation impedes desmopressin treatment success in nocturnal enuresis

2 days ago

Response to desmopressin treatment for nocturnal enuresis in children appears to be compromised in the presence of constipation, particularly in children with severe enuresis and those prescribed low doses, as reported in a recent study.

Enfortumab vedotin shows promise in advanced urothelial cancer

Pearl Toh, 4 days ago

The novel antibody-drug conjugate enfortumab vedotin showed promising clinical activity in patients with advanced and metastatic urothelial cancer for whom there is a high unmet need, according to the EV-201 study presented at the ASCO 2019 Meeting.

Ultrasound guided PCNL as good as conventional PCNL for nephrolithiasis

5 days ago

Performing ultrasound-guided percutaneous nephrolithotomy (US-PCNL) either in prone or supine position is safe and effective as conventional PCNL, with the added benefit of eliminating radiation exposure and its hazards, according to a recent study.

Poor sleep contributes to worse LUTS in nonstandard shift workers

08 Jun 2019

Men working shifts outside of a normal 7 am to 6 pm work day who are at high risk of shift work disorder (SWD) appear to have worse lower urinary tract symptoms (LUTS) than their counterparts who are at low SWD risk, a study reports. However, nonstandard shift work in general is not associated with LUTS.

Uroselective α1A-AR antagonist: A promising agent for the management of BPH

15 Mar 2019

At the Eisai-sponsored tea symposium during the 27th Malaysian Urological Conference at Shangri-La Kuala Lumpur, Professor Osamu Yokoyama highlighted the advantages of silodosin (Urief®, Eisai Inc.) in relieving lower urinary tract symptoms associated with benign prostate hyperplasia.

Nocturia: An inside view on key causes and principles of management

02 Nov 2017

Nocturia is the most prevalent of the lower urinary tract symptoms (LUTS) and can cause a significant negative impact on an individual’s quality of life if left untreated.1,2 In a meeting held at University Malaya Medical Centre, Associate Professor Dr Ong Teng Aik shared his insights on the management of nocturia.

Research sheds light on PARP inhibitor use in mCRPC

Jackey Suen, 06 Mar 2019

The future of poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors in the treatment of metastatic castration-resistant prostate cancer (mCRPC) is promising in light of encouraging results from recent clinical studies.

Immune-checkpoint inhibitors changing the landscape of bladder cancer management

Dr. Joseph Delano Fule Robles, 04 Mar 2019

Since the approval of immune checkpoint inhibitors (ICIs) as standard of care in the second-line setting for metastatic urothelial carcinoma, new approaches on how clinicians manage this condition are emerging.

Robot-assisted radical cystectomy comparable to open cystectomy for urologic cancers

Dr. Joseph Delano Fule Robles, 22 Feb 2019

Studies have demonstrated that robot-assisted radical cystectomy (RARC) is as effective and has a cost advantage compared with open cystectomy for the management of urologic cancers.

Prostate cancer biomarker research gains momentum, but challenges remain

Jackey Suen, 30 Jan 2019

Recent research has revealed various potential biomarkers for metastatic castration-resistant prostate cancer (mCRPC), but several challenges remain in fully utilizing them in clinical practice.

Nanotechnology structured water shows potential for ED treatment

Audrey Abella, 11 May 2018

Nanotechnology structured water was similarly effective as tadalafil in improving erectile function, suggesting that it could be a potential treatment option for erectile dysfunction (ED), according to a study presented at EAU held in Copenhagen, Denmark.

Vibegron shows potential as OAB treatment

Audrey Abella, 30 Apr 2018

The selective β3-adrenoreceptor (AR) agonist vibegron showed superior efficacy over placebo for overactive bladder (OAB) treatment and was generally well-tolerated, according to a Japanese study presented at EAU 2018.

No benefit to targeted antibiotic prophylaxis before TRUS-guided prostate biopsy

Roshini Claire Anthony, 23 Apr 2018

Targeted antibiotic prophylaxis – after a rectal swab to identify specific intestinal flora – does not appear to significantly impact the risk of urinary sepsis following a transrectal ultrasound (TRUS)-guided prostate biopsy, according to a recent study.